[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 1982

Commentary: Treatment of Dermatomycoses With Griseofulvin

Author Affiliations

From the Department of Dermatology, University of Miami School of Medicine.

Arch Dermatol. 1982;118(10):835-836. doi:10.1001/archderm.1982.01650220139020

There is an implied serious responsibility to anyone who introduces a new drug into medicine, especially if its effects will be systemic and it is taken by patients for months or years. Therefore, it was a source of personal satisfaction for me to review Index Medicus back to 1959 and find no clear-cut case of a patient who died of griseofulvin administration. On the contrary, the drug had an enormous worldwide impact for good—curing fungus infections of the scalp, nails, hands, and other areas that were impervious to all previously known treatments. Serious lifetime infections, eg, favus, can now be taught only from old photographs, because the disease that was so mutilating and so common in some countries that special schools had to be established for children has practically disappeared with griseofulvin treatment. Hundreds of articles have appeared from practically every country in the world extolling the value of this

First Page Preview View Large
First page PDF preview
First page PDF preview